Scott, Clare L.

Genome-wide association study identifies novel breast cancer susceptibility loci

Easton, D. F., Pooley, K. A., Dunning, A. M., Pharoah, P. D. P., Thompson, D., Ballinger, D. G., Struewing, J. P., Morrison, J., Field, H., Luben, R., et al. (2007) · Nature

Genetic Associations and EpidemiologyBRCA gene mutations in cancer

Cited by 2,319

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 2,279

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 1,196

SOCS1 Is a Critical Inhibitor of Interferon γ Signaling and Prevents the Potentially Fatal Neonatal Actions of this Cytokine

Alexander, W. S., Starr, R., Fenner, J. E., Scott, C. L., Handman, E., Sprigg, N. S., Corbin, J. E., Cornish, A. L., Darwiche, R., Owczarek, C. M., et al. (1999) · Cell

Cytokine Signaling Pathways and Interactionsinterferon and immune responses

Cited by 762

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

Cragg, M. S., Jansen, E. S., Cook, M., Harris, C., Strasser, A., & Scott, C. L. (2008) · Journal of Clinical Investigation

Melanoma and MAPK PathwaysCell death mechanisms and regulation

Cited by 207

Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics

Cragg, M. S., Harris, C., Strasser, A., & Scott, C. L. (2009) · Nature Reviews Cancer

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 185

Patient-derived Xenograft Models to Improve Targeted Therapy in Epithelial Ovarian Cancer Treatment

Scott, C. L., Becker, M. A., Haluska, P., & Samimi, G. (2013) · Frontiers in Oncology

Ovarian cancer diagnosis and treatmentBRCA gene mutations in cancer

Cited by 100

Molecular and Clinical Predictors of Improvement in Progression‐free Survival with Maintenance PARP Inhibitor Therapy in Women with Platinum‐sensitive, Recurrent Ovarian Cancer: A Meta‐analysis

Lee, C. K., Friedlander, M. L., Tjokrowidjaja, A., Ledermann, J. A., Coleman, R. L., Mirza, M. R., Matulonis, U. A., Pujade‐Lauraine, E., Bloomfield, R., Goble, S., et al. (2021) · Cancer

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 36